FDA Slaps Lupin With Form 483 for Risk of Contamination, Lack of In-Process Testing

Inadequate procedures to minimize the risk of contamination earned Lupin Limited a Form 483 following a March 22 to April 4 FDA inspection of its facility in Palghar, Maharashtra, India.
Source: Drug Industry Daily